乙酰恩格列净
| CAS号 | 915095-99-7 | 货号 | BCP17275 |
| 中文名 | 乙酰恩格列净 | ||
| 英文名 | Acetoxy Empagliflozin | ||
| 中文别名 | |||
| 英文别名 | BI10773; BI-10773; BI 10773; CE0108; CS0940; PB23119; VA10802; AJ93046; | ||
| 分子式 | C30H33ClO11 | 分子量 | 605.03 |
| 生物活性 | Empagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. | ||
| 信号通路 | Ion Channel/Membrane Transporter GPCR/G Protein | ||
| 靶 点 | SGLT | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！